Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Virtual Booth

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

media
5 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 146062-44-4, Leriglitazone, Hydroxy pioglitazone (m-iv), Min-102, Chebi:82937, Leriglitazone [usan]

Molecular Formula

C₁₉H₂₀N₂O₄S

Molecular Weight

372.4 g/mol

InChI Key

OXVFDZYQLGRLCD-UHFFFAOYSA-N

FDA UNII

K824X25AYA

Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

1 2D Structure

Leriglitazone

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

2.1.2 InChI

InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)

2.1.3 InChI Key

OXVFDZYQLGRLCD-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O

2.2 Other Identifiers

2.2.1 UNII

K824X25AYA

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Leriglitazone

2.3.2 Depositor-Supplied Synonyms

1. 146062-44-4

2. Leriglitazone

3. Hydroxy Pioglitazone (m-iv)

4. Min-102

5. Chebi:82937

6. Leriglitazone [usan]

7. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

8. K824x25aya

9. 2,4-thiazolidinedione, 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-

10. 2,4-thiazolidinedione, 5-((4-(2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-

11. Hydroxy Pioglitazone-d4 (m-iv) (deuterated)

12. Hydroxy Pioglitazone

13. 1-hydroxypioglitazone

14. Pioglitazone, Hydroxy

15. Leriglitazone [inn]

16. Leriglitazone (usan/inn)

17. Chembl1267

18. Unii-k824x25aya

19. Schembl4098326

20. Dtxsid30399914

21. Bdbm50530214

22. Who 10868

23. Zinc01482947

24. Akos015856344

25. Db15021

26. 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione

27. Hydroxy Pioglitazone (m-iv Metabolite)

28. Db-042820

29. Hy-117727

30. Cs-0067030

31. Ft-0643388

32. D11603

33. 062h444

34. U-91322

35. A1-01710

36. J-008187

37. Q27156475

38. 5-(4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione

39. 5-(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione

40. 5-[4-[2-[5-(1-hydroxyethyl)-2-pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione

41. All-ambo-5-((4-(2-(5-(1-hydroxyethyl)pyridin-2-yl)ethoxy)phenyl)methyl)-1,3-thiazole-2,4(3h,5h)-dione

2.4 Create Date

2005-09-13

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₀N₂O₄S
Molecular Weight	372.4 g/mol
XLogP3	2.5
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	7
Exact Mass	372.11437830 g/mol
Monoisotopic Mass	372.11437830 g/mol
Topological Polar Surface Area	114 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	496
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	2
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of adrenoleukodystrophy

5 Pharmacology and Biochemistry

5.1 Metabolism/Metabolites

5-[(4-{2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione is a known human metabolite of Pioglitazone.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Leriglitazone manufacturers, exporters & distributors on PharmaCompass

Leriglitazone

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

DIGITAL CONTENT

5 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?